1-Deoxysphingolipid-induced neurotoxicity involves N-methyl-d-aspartate receptor signaling

Neuropharmacology. 2016 Nov;110(Pt A):211-222. doi: 10.1016/j.neuropharm.2016.03.033. Epub 2016 Mar 23.

Abstract

1-Deoxysphingolipids (1-deoxySL) are atypical and neurotoxic sphingolipids formed by alternate substrate usage of the enzyme serine-palmitoyltransferase. Pathologically increased 1-deoxySL formation causes hereditary sensory and autosomal neuropathy type 1 (HSAN1) - a progressive peripheral axonopathy. However, the underlying molecular mechanisms by which 1-deoxySL acts are unknown. Herein we studied the effect of 1-deoxysphinganine (1-deoxySA) and its canonical counterpart sphinganine (SA) in aged cultured neurons comparing their outcome on cell survival and cytoskeleton integrity. 1-deoxySA caused rapid neuronal cytoskeleton disruption and modulated important cytoskeletal regulatory and associated components including Rac1, Ezrin and insulin receptor substrate 53. We show that 1-deoxySA is internalized and metabolized downstream to 1-deoxydihydroceramide since inhibition of ceramide synthase protected neurons from 1-deoxySA-mediated cell death. In addition, 1-deoxySA reduced protein levels of N-methyl-d-aspartate receptor (NMDAR) subunit GluN2B, the postsynaptic density protein 95 and induced cleavage of p35 to p25. Notably, blocking NMDAR activation by MK-801 or memantine significantly prevented 1-deoxySA neurotoxicity. Functional studies of differentiating primary neurons via the patch-clamp technique demonstrated that 1-deoxySA irreversibly depolarizes the neuronal membrane potential in an age-dependent manner. Notably, only neuronal cells that displayed functional NMDAR- and NMDA-induced whole-cell currents responded to 1-deoxySA treatment. Furthermore, pre-exposure to the non-competitive antagonist MK-801 blocked the current response of NMDA and glycine, as well as 1-deoxySA. We conclude that 1-deoxySA-induced neurotoxicity compromises cytoskeletal stability and targets NMDAR signaling in an age-dependent manner. Thus stabilization of cytoskeletal structures and/or inhibition of glutamate receptors could be a potential therapeutic approach to prevent 1-deoxySA-induced neurodegeneration.

Keywords: Cytoskeleton; Hereditary sensory and autosomal neuropathy type 1; Lipid metabolism; NMDA receptor; Rac1.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Cell Line, Tumor
  • Cerebral Cortex
  • Cytoskeleton / drug effects
  • Cytoskeleton / metabolism
  • Disks Large Homolog 4 Protein / metabolism
  • Dizocilpine Maleate / pharmacology
  • Dose-Response Relationship, Drug
  • Excitatory Amino Acid Antagonists / pharmacology
  • Glycine / administration & dosage
  • Glycine / metabolism
  • Humans
  • Memantine / pharmacology
  • Membrane Potentials / drug effects
  • Membrane Potentials / physiology
  • Mice, Inbred C57BL
  • N-Methylaspartate / administration & dosage
  • N-Methylaspartate / metabolism
  • Neurons / drug effects*
  • Neurons / metabolism*
  • Neurons / pathology
  • Neuroprotective Agents / pharmacology
  • Receptors, N-Methyl-D-Aspartate / antagonists & inhibitors
  • Receptors, N-Methyl-D-Aspartate / metabolism*
  • Signal Transduction / drug effects
  • Sphingolipids / toxicity*
  • Sphingosine / analogs & derivatives
  • Sphingosine / toxicity
  • rac1 GTP-Binding Protein / antagonists & inhibitors
  • rac1 GTP-Binding Protein / metabolism

Substances

  • 1-deoxysphingolipid
  • Disks Large Homolog 4 Protein
  • Excitatory Amino Acid Antagonists
  • Neuroprotective Agents
  • Receptors, N-Methyl-D-Aspartate
  • Sphingolipids
  • N-Methylaspartate
  • Dizocilpine Maleate
  • rac1 GTP-Binding Protein
  • Sphingosine
  • safingol
  • Glycine
  • Memantine